Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.42 |
| ▸ | DUT | P33316 | 2/20 | 0.42 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6693614 | 0.95 | CHRNA7 (0.43) | HIF1ACHRNA7DUTTRAP1 | |
| Bromide SCHEMBL8901702 | 0.94 | CHRNA7 (0.45) | HIF1ACHRNA7DUTTRAP1 | |
| Bromide SCHEMBL10706995 | 0.94 | CHRNA7 (0.45) | HIF1ACHRNA7DUTTRAP1 | |
| Bromide SCHEMBL16197658 | 0.94 | CHRNA7 (0.45) | HIF1ACHRNA7DUTTRAP1 | |
| Iodide SCHEMBL15377774 | 0.91 | CHRNA7 (0.48) | HIF1ACHRNA7DUTTRAP1 | |
| Iodide SCHEMBL28884356 | 0.91 | CHRNA7 (0.48) | HIF1ACHRNA7DUTTRAP1 | |
| Bromide SCHEMBL7471956 | 0.82 | CHRNA7 (0.40) | HIF1ACHRNA7TRAP1 | |
| Bromide SCHEMBL8436730 | 0.78 | CHRNA7 (0.49) | HIF1ACHRNA7TRAP1 | |
| SCHEMBL13527885 | 0.76 | SIGMAR1 (0.44) | DUT | |
| Bromide SCHEMBL9396781 | 0.76 | CHRNA7 (0.40) | HIF1ACHRNA7TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116848122-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3476832-B1 | CATIONIC LIPID | EISAI R&D MAN CO LTD (JP) | 2023-04-19 | — | — | EP | disclosed |
| CN-109311809-B | Cationic lipids | 卫材R&D管理有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190218180-A1 | Cationic Lipid | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-07-18 | — | — | US | disclosed |
| EP-3476832-A1 | CATIONIC LIPID | Eisai R&D Management Co., Ltd. (JP) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20160090383-A1 | ANTIBACTERIAL PHTHALIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-31 | — | — | US | disclosed |
| US-7087630-B2 | Cyclooxygenase 2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1534683-A4 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050119242-A1 | Vitamin D analogs for obesity prevention and treatment | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-06-02 | — | — | US | disclosed |
| EP-1534683-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040229851-A1 | 2-Propylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-11-18 | — | — | US | disclosed |
| US-20040127718-A1 | Substituted imidazoles | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | US | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004002409-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030181479-A1 | Substituted imidazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| US-5439899-A | A cholestanes for treating human T-cell leukemia/lymphoma viruses | PURDUE RESEARCH FOUNDATION (US) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | HIF1A 270/4885CHRNA7 4626/4885DUT 159/4885 |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | HIF1A 3231/4885CHRNA7 994/4885DUT 3097/4885 |
| US-20190218180-A1 | Cationic Lipid | NPC1L1, NPC1, LPCAT1 | HIF1A 1739/4885CHRNA7 2425/4885DUT 2688/4885 |
| US-20030181479-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | HIF1A 1949/4885CHRNA7 123/4885DUT 3080/4885 |
| US-20040127718-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | HIF1A 1949/4885CHRNA7 123/4885DUT 3080/4885 |
| US-20040229851-A1 | 2-Propylidene-19-nor-vitamin D compounds | VDR, CD14, CYP24A1 | HIF1A 2894/4885CHRNA7 2856/4885DUT 2697/4885 |
| US-20050119242-A1 | Vitamin D analogs for obesity prevention and treatment | VDR, CYP24A1, SCD | HIF1A 576/4885CHRNA7 4094/4885DUT 1627/4885 |
| US-20160090383-A1 | ANTIBACTERIAL PHTHALIDE DERIVATIVES | MRPL21, MAPRE1, HDAC6 | HIF1A 821/4885CHRNA7 4869/4885DUT 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.